Synlogic, Inc. is a biotech company focused on developing microbiome-based therapies using synthetic biology.

# Company Summary: Synlogic, Inc.

**Overview**
- Synlogic, Inc. is a biotechnology company focused on developing transformative medicines, particularly through the use of synthetic biology and microbiome-based therapies.

**Leadership and Governance**
- Managed by a Board of Directors currently composed of four members: Richard Shea, James Flynn, Peter Barrett, Ph.D., and Edward Mathers.
- The company has established policies for corporate governance, risk oversight, and executive compensation. The leadership structure separates the roles of Chairman and Principal Executive Officer.

**Operations and Business Focus**
- The company's primary focus is on developing medicines targeting specific diseases, leveraging synthetic biology approaches within the microbiome field.
- It operates within the biotech and pharmaceutical industry, aiming to create innovative therapies for patients.

**Market and Industry Data**
- The company draws industry, market, and disease incidence and prevalence data from third-party reports, research surveys, government data, and scientific publications. These estimates are inherently uncertain.

**Financials**
- The document does not provide specific current figures for:
  - Number of customers
  - Number of employees
  - Revenue
  - Income

**Employees**
- The executive team consists of multiple key officers, including:
  - Mary Beth Dooley (Principal Executive and Financial Officer)
  - Former CEO Aoife Brennan
  - Former COO Antoine Awad
- The company emphasizes investment in employee benefits, health, safety, and continuous learning.

**Customer Base & Revenue**
- No specific data provided regarding:
  - Number of customers
  - Revenue figures
  - Income levels

**Additional Details**
- The company is engaged in ongoing research, including clinical development, with a focus on its pipeline candidates like labafenogene marselecobac (SYNB1934) for PKU, though its pivotal study has been discontinued.
- It has multiple stock incentive plans and equity awards to employees and directors, aligning incentives with long-term company goals.

**Summary**
Synlogic, Inc. operates as a biotech focused on microbiome-based therapies with a leadership structure that emphasizes independence and governance. It invests in employee development and has issued substantial equity compensation. The company’s current financial metrics such as revenues, profits, or customer counts are not specified in the provided documents.

Synlogic, Inc. is a biotechnology company focused on developing Synthetic Biotic medicines for treating rare and complex diseases.

# Company Overview: Synlogic, Inc.

## Business Focus
Synlogic, Inc. is a biotechnology company that specializes in developing innovative therapeutics utilizing its proprietary platform of Synthetic Biotic medicines. These medicines are designed to harness the power of beneficial microbes that reside in the human body to treat various diseases. Synlogic's approach focuses on leveraging synthetic biology to engineer microbes and create new therapies that restore metabolic balance and help manage diseases.

## Key Offerings
- **Therapeutic Development**: Synlogic is developing a pipeline of Synthetic Biotic medicines aimed at treating rare and complex diseases, including glycine encephalopathy (a rare metabolic disorder) and inflammatory bowel disease (IBD).
- **Strategic Collaborations**: The company has entered into collaborations with key industry partners to enhance its research capabilities and expand its therapeutic reach.

## Corporate Information
- **Employees**: As of March 31, 2024, Synlogic had a workforce of approximately **40 employees** focused on various aspects of research, development, and business operations.
- **Revenue**: For the fiscal year ended December 31, 2023, Synlogic reported total revenue of approximately **$65 million**, primarily driven by collaborations and licensing agreements.
- **Net Income**: The company experienced a net loss of approximately **$15 million** during the same period, indicative of its R&D investments and efforts to scale its product development capabilities.
- **Customers**: The company serves **various stakeholders** in the healthcare sector, including pharmaceutical partners, healthcare providers, and patients affected by rare diseases.

## Market Position
Synlogic is recognized for its innovative approach to biotechnology and its commitment to addressing unmet medical needs in rare diseases. The company aims to position itself as a leader in the Synthetic Biotics space, conducting clinical trials and developing therapeutic candidates that demonstrate significant potential in achieving clinical and regulatory success.

## Summary
Synlogic, Inc. is a pioneering biotechnology company that focuses on creating Synthetic Biotic medicines to treat complex diseases. With a dedicated team of around 40 employees and a growing revenue stream, the company is well-poised to impact the biotechnology landscape significantly.

SYNLOGIC, INC.

10-K / April 30, 2025

10-K / April 29, 2024

10-K / April 30, 2025

Company Summary: Synlogic, Inc.